Andrés Vargas1,2, Katarzyna Holub3, Albert Biete3. 1. Radiation Oncology Department, Instituto de Radiomedicina (IRAM), Avenida Américo Vespucio 1314, Vitacura, 7630000, Santiago de Chile, Chile. andres.vargas@iram.cl. 2. Facultad de Medicina, Universidad Diego Portales, Santiago, Chile. andres.vargas@iram.cl. 3. Facultat de Medicina, Universitat de Barcelona, C/Casanova 143, 08036, Barcelona, Spain.
Abstract
BACKGROUND: Breast cancer (BC) prevalence steadily increases in older patients but their treatment is based on the geriatric evaluations of comorbidities and potential benefits proved in clinical trials with younger patients. The lack of better decision-making tools urges to promote the search for new prognostic markers. The association between inflammation, aging and cancer may be crucial for better treatment selection. We sought to analyze its impact on the survival of older BC patients, evaluating the interaction with age and comorbidities. METHODS: We evaluated the relationship between inflammatory biomarkers at BC diagnosis (circulating blood cell counts and inflammatory indexes) and BC-related and not related mortality rate, evaluating the influence of comorbidities and age through the competitive risks assessment. RESULTS: We analyzed 148 consecutive BC patients aged ≥ 70 years old, diagnosed with BC and regional lymph node metastases. After the median follow-up of 51.5 months, 59 patients died (28 due to breast cancer progression and 31 because of other causes). Increased levels of circulating monocytes, neutrophils and neutrophil-to-lymphocytes ratio and decreased level of eosinophils and eosinophil multiple by neutrophils-to-lymphocytes ratio were associated with higher probability of BC-related death but not with death related to other causes. CONCLUSION: Our data suggest a role of inflammatory parameters as a possible prognostic tool in therapeutic decision-making process in older patients with BC, as increased level of inflammation was associated with cancer-specific mortality. Prospective studies may give the possibility of refining the geriatric evaluation for BC treatment in elderly.
BACKGROUND: Breast cancer (BC) prevalence steadily increases in older patients but their treatment is based on the geriatric evaluations of comorbidities and potential benefits proved in clinical trials with younger patients. The lack of better decision-making tools urges to promote the search for new prognostic markers. The association between inflammation, aging and cancer may be crucial for better treatment selection. We sought to analyze its impact on the survival of older BC patients, evaluating the interaction with age and comorbidities. METHODS: We evaluated the relationship between inflammatory biomarkers at BC diagnosis (circulating blood cell counts and inflammatory indexes) and BC-related and not related mortality rate, evaluating the influence of comorbidities and age through the competitive risks assessment. RESULTS: We analyzed 148 consecutive BC patients aged ≥ 70 years old, diagnosed with BC and regional lymph node metastases. After the median follow-up of 51.5 months, 59 patients died (28 due to breast cancer progression and 31 because of other causes). Increased levels of circulating monocytes, neutrophils and neutrophil-to-lymphocytes ratio and decreased level of eosinophils and eosinophil multiple by neutrophils-to-lymphocytes ratio were associated with higher probability of BC-related death but not with death related to other causes. CONCLUSION: Our data suggest a role of inflammatory parameters as a possible prognostic tool in therapeutic decision-making process in older patients with BC, as increased level of inflammation was associated with cancer-specific mortality. Prospective studies may give the possibility of refining the geriatric evaluation for BC treatment in elderly.
Authors: C Franceschi; M Bonafè; S Valensin; F Olivieri; M De Luca; E Ottaviani; G De Benedictis Journal: Ann N Y Acad Sci Date: 2000-06 Impact factor: 5.691
Authors: Esther Bastiaannet; Johanneke E A Portielje; Cornelis J H van de Velde; Anton J M de Craen; Susanne van der Velde; Peter J K Kuppen; Lydia G M van der Geest; Maryska L G Janssen-Heijnen; Olaf M Dekkers; Rudi G J Westendorp; Gerrit-Jan Liefers Journal: Oncologist Date: 2011-03-15
Authors: Laura Biganzoli; Nicolò Matteo Luca Battisti; Hans Wildiers; Amelia McCartney; Giuseppe Colloca; Ian H Kunkler; Maria-João Cardoso; Kwok-Leung Cheung; Nienke Aafke de Glas; Rubina M Trimboli; Beatriz Korc-Grodzicki; Enrique Soto-Perez-de-Celis; Antonio Ponti; Janice Tsang; Lorenza Marotti; Karen Benn; Matti S Aapro; Etienne G C Brain Journal: Lancet Oncol Date: 2021-05-14 Impact factor: 41.316